98%
921
2 minutes
20
Background: Psycho-oncological services (POS) are an integral and widely recommended part of comprehensive cancer care. However, their utilisation appears to fall short of the perceived need. This study aimed to explore barriers and facilitators for the uptake of POS in the context of existing clinical structures and pathways to POS.
Methods: A mixed-methods study was conducted, drawing on elements of a Delphi approach, including an iterative two-round feedback process and an expert panel. The expert panel consisted of healthcare professionals in cancer care ( = 27) and cancer patients ( = 14). The first round comprised open-ended questions to explore different perspectives related to the research question. The resulting material was analysed qualitatively and grouped into themes, which were rated according to their perceived importance by the expert panel in the second survey-round ( = 27).
Results: The expert panel identified 69 aspects influencing the uptake of POS; 81% were rated as relevant in the second round. They were grouped into structural factors at hospital level, aspects related to internal processes, and factors at patient level. Central aspects were recommendations of POS by the clinical staff, personal introduction of the psycho-oncologist, integration and acceptance of POS within the hospital organisation, information dissemination about POS to both patients and clinical staff, and the possibility of flexible access routes to POS since patients’ preferences differed. Patient-groups more difficult to reach with a POS-offer were also identified.
Conclusion: The results can be used to review implemented clinical pathways to POS in diverse hospital contexts, helping to identify and improve critical aspects accordingly, and thus improve service accessibility.
Trial Registration: This study was pre-registered at the German Clinical Trials Register (DRKS-ID: DRKS00025105; registration date: 26-05-2021).
Supplementary Information: The online version contains supplementary material available at 10.1186/s12913-025-13053-5.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12220343 | PMC |
http://dx.doi.org/10.1186/s12913-025-13053-5 | DOI Listing |
A cross-sectional online survey was conducted. A high proportion of the Chinese breast cancer (BC) physician respondents (n=77) would prescribe extended adjuvant endocrine therapy (AET) with aromatase inhibitors (AI) beyond 5 years for postmenopausal females with BC, especially those with higher risk. Respondents with ≥15 years of clinical experience were more likely to prescribe a longer duration of AET for low-risk patients.
View Article and Find Full Text PDFJ Am Med Inform Assoc
March 2007
American Medical Informatics Association, 4915 St. Elmo Avenue, Suite 401, Bethesda, MD 20814, USA.
Secondary use of health data applies personal health information (PHI) for uses outside of direct health care delivery. It includes such activities as analysis, research, quality and safety measurement, public health, payment, provider certification or accreditation, marketing, and other business applications, including strictly commercial activities. Secondary use of health data can enhance health care experiences for individuals, expand knowledge about disease and appropriate treatments, strengthen understanding about effectiveness and efficiency of health care systems, support public health and security goals, and aid businesses in meeting customers' needs.
View Article and Find Full Text PDF